EGFR and non-small cell lung carcinoma: After variant annotation and actionability characterization, we examined the prevalence and evolving comutation patterns across serial pCGP, focusing on genomic mechanisms of tyrosine kinase inhibitor (TKI)-acquired resistance in EGFR-mutant NSCLC.